Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kiniksa Pharmaceuticals Ltd.

27.65
-0.0900-0.32%
Post-market: 27.650.00000.00%19:39 EDT
Volume:662.35K
Turnover:18.37M
Market Cap:2.02B
PE:-117.33
High:28.06
Open:27.78
Low:27.43
Close:27.74
Loading ...

Kiniksa Pharmaceuticals Announces GRAMMY® Award-Winning Country Star, Carly Pearce, Joins the Life DisRPted™ Campaign, Adding to Voices Advocating for Awareness of Recurrent Pericarditis

GlobeNewswire
·
30 Apr

An Intrinsic Calculation For Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Suggests It's 41% Undervalued

Simply Wall St.
·
30 Apr

Kiniksa Pharmaceuticals Is Maintained at Buy by Jefferies

Dow Jones
·
30 Apr

Wedbush Raises Price Target on Kiniksa Pharmaceuticals to $36 From $34, Maintains Outperform Rating

MT Newswires Live
·
30 Apr

Honeywell Posts Better-Than-Expected Q1 Earnings, Joins Crown Holdings, Noble, Crane And Other Big Stocks Moving Higher On Tuesday

Benzinga
·
29 Apr

Kiniksa Pharmaceuticals Swings to Q1 Net Income, Revenue Increases

MT Newswires Live
·
29 Apr

Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q1 Earnings and Revenue Estimates

Zacks
·
29 Apr

Earnings Flash (KNSA) Kiniksa Pharmaceuticals International Posts Q1 EPS $0.11, vs. FactSet Est of $0.13 per Share

MT Newswires Live
·
29 Apr

Kiniksa Pharmaceuticals Q1 GAAP EPS $0.11 Misses $0.14 Estimate, Sales $137.78M Miss $140.68M Estimate

Benzinga
·
29 Apr

BRIEF-Kiniksa Pharmaceuticals Q1 EPS USD 0.12

Reuters
·
29 Apr

Kiniksa Pharmaceuticals International Plc: Expects 2025 Arcalyst Net Product Revenue of Between $590 Million and $605 Million

THOMSON REUTERS
·
29 Apr

Kiniksa Pharmaceuticals Q1 Pretax Profit USD 15.565 Million

THOMSON REUTERS
·
29 Apr

Kiniksa Pharmaceuticals International Plc: Kpl-387 Phase 2/3 Clinical Trial in Recurrent Pericarditis on Track to Initiate in Mid-2025

THOMSON REUTERS
·
29 Apr

Kiniksa Pharmaceuticals Reports First Quarter 2025 Financial Results and Recent Portfolio Execution

GlobeNewswire
·
29 Apr

uniQure (QURE) Moves 38.5% Higher: Will This Strength Last?

Zacks
·
21 Apr

Kiniksa Pharmaceuticals Price Target Maintained With a $34.00/Share by Wedbush

Dow Jones
·
16 Apr

Is Kiniksa Pharmaceuticals (KNSA) Outperforming Other Medical Stocks This Year?

Zacks
·
08 Apr

Wall Street Analysts Predict a 64.8% Upside in Kiniksa Pharmaceuticals (KNSA): Here's What You Should Know

Zacks
·
04 Apr

How Much Upside is Left in Kiniksa Pharmaceuticals (KNSA)? Wall Street Analysts Think 58.6%

Zacks
·
19 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Metropolitan Bank, Fossil, MeiraGTx

Reuters
·
13 Mar